

MeIn/03/Olm-Hyp/001

Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension. Randomised, double blind, active-control study in two parallel groups of patients with mild to moderate hypertension.

This study has completed the enrolment of patients

Sponsor: : Menarini International Operations Luxembourg S.A.

Intervention: Olmesartan medoxomil 10-40 mg, tablets, once daily
Ramipril 2.5-10 mg, tablets, once daily

Condition: Mild to Moderate Essential Hypertension

This study is designed to assess the effects and safety of the administration of **olmesartan, compared with ramipril**, in elderly patients with hypertension. The efficacy will be primarily evaluated through the Diastolic Blood Pressure at week 12. In addition, long term efficacy and safety of olmesartan 40 mg will also be assessed.

Study type & design: Multi-centre, double-blind, active-controlled, parallel-group, randomized study

Main criteria for inclusion:

Male or female outpatients, aged 65-89 years, with mild to moderate essential hypertension (sDBP \geq 90mmHg and sSBP \geq 140mmHg)

Main criteria for exclusion:

Grade 3, secondary or malign arterial hypertension.
Contraindications for ARBs or ACE-i. Unstable angina. Cardiac arrhythmia, heart failure requiring medical treatment.